Reata’s Rare Genetic Disorder Drug gets US FDA Approval
Reata Pharmaceuticals Inc.’s drug for the treatment of a rare genetic disorder that causes progressive damage to the nervous system was approved by the U.S. Food and Drug Administration (FDA), prompting its shares to rise nearly 160% after the opening bell. Skyclarys, Reata’s first approved product, is expected to sell for $400 million in the […]
Continue Reading